 REDWOOD CITY, Calif., Dec. 22, 2020 GLOBE NEWSWIRE -- Allakos Inc. NASDAQ: ALLK, a biotechnology company developing lirentelimab AK002 for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of Audentes Therapeutics, to the Allakos board of directors. 